Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2a Clinical Trial in Early Acute Spinal Cord Injury (SCI): a Single Blinded, Randomized, Proof-of-Concept Study to Determine the Safety, Tolerability and Efficacy of TZ-161

NCT06677229 is registered in ClinicalTrials.gov with Technophage, SA as lead sponsor.

NCT NCT06677229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06677229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2a Clinical Trial in Early Acute Spinal Cord Injury (SCI): a Single Blinded, Randomized, Proof-of-Concept Study to Determine the Safety, Tolerability and Efficacy of TZ-161
Lead sponsor
Technophage, SA
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 1, 2025
Completion date
June 30, 2027
Enrollment
28 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute spinal cord injury (sci)